Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | HCAR2 | Q8TDS4 | 11/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | HCAR3 | P49019 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | ALPL | P05186 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20525153 | 0.87 | MAPK1 (0.56) | MAPK1HCAR2POLBRAB9ANPC1 | |
| SCHEMBL28835655 | 0.84 | HCAR2 (0.66) | MAPK1HCAR2POLBRAB9ANPC1 | |
| SCHEMBL17376787 | 0.84 | HCAR2 (0.62) | MAPK1HCAR2POLBRAB9ANPC1 | |
| SCHEMBL20525148 | 0.83 | KMT2A (0.50) | HCAR2POLBKMT2AL3MBTL1HCAR3 | |
| SCHEMBL24963148 | 0.83 | MAPK1 (0.59) | MAPK1HCAR2POLBRAB9ANPC1 | |
| SCHEMBL11089590 | 0.83 | MAPK1 (0.59) | MAPK1HCAR2POLBRAB9ANPC1 | |
| SCHEMBL15777079 | 0.81 | MAPK1 (0.57) | MAPK1HCAR2POLBRAB9ANPC1 | |
| SCHEMBL26115950 | 0.81 | HCAR2 (0.68) | MAPK1HCAR2POLBRAB9ANPC1 | |
| SCHEMBL7372956 | 0.78 | HCAR2 (0.69) | HCAR2HCAR3 | |
| SCHEMBL3624738 | 0.78 | MAPK1 (0.67) | MAPK1HCAR2POLBRAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8785489-B2 | Heteroaryl substituted indole compounds useful as MMP-13 inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-07-22 | — | — | US | disclosed |
| US-20110275631-A1 | Heteroaryl Substituted Indole Compounds Useful as MMP-13 Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275631-A1 | Heteroaryl Substituted Indole Compounds Useful as MMP-13 Inhibitors | MMP13, MMP3, MMP11 | MAPK1 2286/4885HCAR2 979/4885POLB 1008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.